ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Sjögren’s syndrome"

  • Abstract Number: 1889 • ACR Convergence 2024

    Prevalence of Physician-Diagnosed versus Clinically Confirmed Primary Sjögren’s Syndrome (SS) Among Adults in the United States

    Cynthia J. Willey1, Sarah N. Ali2 and Rieke Alten3, 1College of Pharmacy, University of Rhode Island, Kingston, RI, 2Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, 3Schlosspark Klinik, University Medicine Berlin, Berlin, Germany

    Background/Purpose: Sjögren’s Syndrome (SS) is a systemic autoimmune disorder characterized by inflammation of salivary and lachrymal glands. The clinical spectrum is variable as slow progressive…
  • Abstract Number: 2299 • ACR Convergence 2024

    Clinical and Serological Characteristics of Sjögren’s Disease-related Lymphocytic Interstitial Pneumonia: A Large Multicenter Study

    Gaetano La Rocca1, Francesco Ferro2, Marco Sebastiani3, Andreina Manfredi4, Caterina Vacchi5, Elena Bartoloni Bocci6, Martina Nicchi7, Fabiola Atzeni8, Francesca Cracò9, Serena Guiducci10, Laura Cometi11, Luca Quartuccio12, Elena Treppo12, Valeria manfrè13, Marta Mosca1 and Chiara Baldini1, and Italian Study group on Lung iNvolvement in rheumatic Diseases (ISLaND), 1University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, 2Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, 3Rheumatology Unit, Azienda USL of Piacenza and University of Parma, Parma, Italy, 4University of Modena and Reggio Emilia, Modena, 5University of Modena and Reggio Emilia, Modena, Italy, 6Rheumatology Unit. Department of Medicine, Perugia, Perugia, Italy, 7Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, 8University of Messina, Italy, Messina, Italy, 9University of Messina, Messina, Italy, 10University of Florence, Pistoia, Italy, 11University of Florence, Florence, Italy, 12Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, Udine, Italy, 13University of Udine, Udine

    Background/Purpose: Interstitial Lung Disease (ILD) in patients with Primary Sjögren’s Disease (SjD) is very heterogeneous in terms of pathophysiologic mechanisms, clinical course, radiologic and histologic…
  • Abstract Number: 2629 • ACR Convergence 2024

    Deciphering Salivary Gland Inflammation in Sjögren’s Syndrome Reveals Shared and Autoantibody-Specific Immune Cell Heterogeneity

    Jun Inamo1, Masaru Takeshita2, Katsuya Suzuki2, Kazuyuki Tsunoda2, Satoshi Usuda2, Junko Kuramoto2, Tsutomu Takeuchi3 and Yuko Kaneko4, 1University of Colorado School of Medicine, Aurora, CO, 2Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 3Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, 4Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, JP, Shinjuku-ku, Tokyo, Japan

    Background/Purpose: Sjögren's syndrome (SS) is an autoimmune disease characterized by progressive immune cell-mediated destruction of the exocrine glands. SS patients have distinct clinical phenotypes based…
  • Abstract Number: 1247 • ACR Convergence 2024

    Pre- and Post-Diagnosis Comparison of the Patient Experience of Sjögren’s Syndrome (SS): A Linguistic Analysis of Global Social Media Conversations

    Sarah N. Ali1, Dorothee Oberdhan1, Michelle M. Richardson1, Jordan Amorelli2, Amanda Martini2 and Jennifer Dandy2, 1Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, 2Real Chemistry, New York, NY

    Background/Purpose: Patients with Sjögren’s Syndrome (SS) often undergo a prolonged and complex path to diagnosis and experience symptom, disease and treatment burdens with multiple co-morbid…
  • Abstract Number: 1421 • ACR Convergence 2024

    Differential Impact of B-cell Targeted Monotherapy and Combination Regimen on the Peripheral Blood Transcriptome of Adults with Active Sjögren Disease

    Coziana Ciurtin1, Lucia Martin-Gutierrez1, John Casement2, Kyle Thompson3, Fai Ng4, Andre van Maurik5 and Elizabeth Jury1, 1University College London, London, United Kingdom, 2Newcastle University, Newcastle, United Kingdom, 3Newcastle University, Newcastle, England, United Kingdom, 4Newcastle University, Newcastle upon Tyne, England, United Kingdom, 5Precision Medicine, GlaxoSmithKline, Stevenage, United Kingdom

    Background/Purpose: Sjögren disease (SD) is characterised by B-cell hyperactivity associated with increased levels of B-lymphocyte stimulator (BlyS), but there are no effective biologic treatments for…
  • Abstract Number: 1909 • ACR Convergence 2024

    Racial Disparities in Ocular Complications of Systemic Rheumatic Diseases: A Retrospective Cross-Sectional Study

    Insa Mannstadt1, Yiyuan Wu2 and Bella Mehta3, 1Columbia University VP&S, New York, NY, 2Weill Cornell Medicine, New York, NY, 3Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: While systemic rheumatic diseases, including Sjogren's syndrome, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and spondyloarthropathies, are known to have severe ophthalmologic manifestations, there…
  • Abstract Number: 2300 • ACR Convergence 2024

    Activation of Tissue-Resident T Cells in Sjögren’s Disease with Human Salivary Organoids

    Brandon Law1, Rahmatullah Rahmati2 and Andrew Luster3, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts Eye & Ear, Boston, MA, 3Massachusetts General Hospital, Charlestown, MA

    Background/Purpose: Sjögren's disease (SjD) is a chronic autoimmune disease characterized by lymphocytic infiltration of exocrine glands, particularly the salivary glands. These focal lymphocytic infiltrates are…
  • Abstract Number: 2630 • ACR Convergence 2024

    Identification of Molecular Biomarkers for Sjögren’s Disease Stratification via a Deep Learning Foundation Model Dedicated to Immune-Mediated and Inflammatory Disease

    Aygalic Jara-Mikolajczak1, Zachary Abessera1, Martin Rethoret-Pasty1, Elisa Mazuir1, Apolline Bruley1, Wan Fai Ng2, Marta Alarcon-Riquelme3, Michele Bombardieri4, Simon Bowman5, Elena Pontarini6, Jacques-Eric Gottenberg7, Xavier Mariette8, Laurence LAIGLE9, Julien Duquesne1, Philippe Moigeon10 and Vincent Bouget11, and NECESSITY Consortium, 1Scienta Lab, Paris, France, 2Department of Rheumatology, Newcastle University, & HRB Clinical Research Facility, University College Cork, Newcastle upon Tyne, United Kingdom, 3Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 4Centre for Experimental Medicine and Rheumatology, The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, 5Department of Rheumatology, University Hospital Birmingham, Birmingham, United Kingdom, 6William Harvey Research Institute, London, United Kingdom, 7Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, 8Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, 9Servier Laboratories, France, SURESNES, France, 10Servier Laboratories, France, Gif sur Yvette, France, 11Scienta Lab, Gif-sur-Yvette, France

    Background/Purpose: Sjögren’s Disease (SjD) exhibits heterogeneity in clinical manifestations and underlying biology. This heterogeneity complicates drug development, with no targeted therapy approved to date. Identifying…
  • Abstract Number: 1250 • ACR Convergence 2024

    Qualitative Study on Patient-Reported Outcome Measures in Patients with Sjögren’s Disease

    Suzanne Arends1, Jiyoon C. Choi2, Brandon Becker2, Teresa Edwards3, Antoine Sreih4, Antonia Christodoulou4 and Vibeke Strand5, 1Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2Bristol Myers Squibb, Princeton, 3RTI International, Research Triangle Park, NC, 4Bristol Myers Squibb, Princeton, NJ, 5Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA

    Background/Purpose: Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease characterized by lymphocytic infiltration of the endocrine glands. Globally, SjD affects between 0.01% and 0.05%…
  • Abstract Number: 1422 • ACR Convergence 2024

    Evaluation of Salivary Gland Focus Score in Sjogren’s Disease Using Deep Learning: A Step Towards Tissue Biomarker Discovery

    Konstantinos Panagiotopoulos1, Nikos Tsiknakis2, Dimitrios Zaridis3, Athanasios Tzioufas4, Dimitrios I. Fotiadis5 and Andreas Goules6, 1Pathophysiology Department, National and Kapodistrian University of Athens, Athens, Greece, 2Karolinska Institutet, Department of Oncology-Pathology, Computational BioMedicine Laboratory, Foundation for Research and Technology Hellas, Stockholm, Sweden, 3School of Electrical & Computer Engineering and Biomedical Research Institute National Technical University of Athens and FORTH, Unit of Medical Technology and Intelligent Information Systems, Department of Materials Science and Engineering, University of Ioannina, Ioannina, Ioannina, Greece, 4LAIKO HOSPITAL, Athens, Greece, 5Unit of Medical Technology and Intelligent Information Systems, University of Ioannina & FORTH, Ioannina, Greece, 6GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece

    Background/Purpose: Sjogren's Disease (SjD) is characterized by focal sieladenitis in minor salivary gland biopsies (mSGB), which is evaluated using the Focus Score (FS). FS ≥…
  • Abstract Number: 1961 • ACR Convergence 2024

    Salivary and Lacrimal Glands Ultrasonography in Systemic Lupus Erythematosus Patients

    Mohammadrafi Damirchi1, Nafiseh Abdolahi2, Fatemeh Hosseini3, Mohadeseh Mohammadi3, Mina Khosravi4, Zahra Niakan1 and Siavash Abbasi3, 1Golestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran, Gorgan, Iran, 2Golestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran, Melbourne, Australia, 3Department of Radiology, Golestan University of Medical Sciences, Gorgan, Iran, Gorgan, Iran, 4Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran, Tehran, Iran

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune inflammatory condition that can manifest in various ways, such as oral and eye-related symptoms, which may overlap…
  • Abstract Number: 2301 • ACR Convergence 2024

    The Added Value of anti-Ro52 Antibody Titer in the Diagnosis of Sjögren’s Disease

    Silvia Fonzetti1, Caterina Porciani2, Valentina Donati3, Davide Testa4, Giovanni Fulvio1, Gaetano La Rocca1, Inmaculada Conception Navarro García1, Francesco Ferro5, Marta Mosca1, Paola Migliorini6 and Chiara Baldini1, 1University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, 2University of Pisa, Department of Clinical and Experimental Medicine - Immmunology and Allergology Unit, Pisa, Italy, 3Azienda Ospedaliero-Universitaria Pisana, Unit of Pathological Anatomy 2, Pisa, Italy, 4Immunology Unit, University of Pisa, Pisa, 5Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, 6Immunology Unit, University of Pisa, Pisa, Italy

    Background/Purpose: Isolated anti-Ro52 antibodies (anti-Ro52) influence the ACR/EULAR 2016 classification criteria of Sjögren’s Disease (SD), meaning that patients with isolated anti-Ro52 positivity and abnormal salivary…
  • Abstract Number: 2631 • ACR Convergence 2024

    Risk of Atherosclerotic Cardiovascular Events and Venous Thromboembolism in People with Primary Sjögren’s Syndrome: A Danish Cohort Study

    Pierre Loiseau1, Aurélie Mailhac2, Pierre Duhaut1, Henrik Toft Sørensen2 and Reimar W Thomsen2, 1Department of Internal Medicine and RECIF, Amiens-Picardie University Hospital, Amiens, France, 2Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark

    Background/Purpose: There is evidence of an increased risk of cardiovascular disease in several autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. In primary…
  • Abstract Number: 1406 • ACR Convergence 2024

    Development and Functional Characterization of Salivary Gland Organoids to Investigate Sjögren’s Disease

    Negaar Goudarzi1, Loïc Meudec2, Juliette Pascaud2, Fanny Jaulin3, Quentin Pascal4, Thierry Lazure5, Sacha E Silva Saffar2, Xavier Mariette6 and Gaetane Nocturne6, 1University Paris-Saclay, Le Kremlin Bicêtre, France, 2University Paris Saclay, Le Kremlin Bicetre, France, 3Institut Gustave Roussy, Villejuif, France, 4CEA, Fontenay aux roses, France, 5APHP. Université Paris-Saclay, Hôpital Bicêtre, Anatomie et cytologie pathologiques, Paris, France, 6Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France

    Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune disease that manifests as glandular dryness and systemic symptoms. Salivary gland epithelial cells (SGEC) are pivotal in…
  • Abstract Number: 1423 • ACR Convergence 2024

    An Observational Analytical Study on HCV Patients with Sicca Manifestations Before and After Direct-Acting Antivirals in Comparison with Sjogren’s Disease; Infection versus Autoimmunity

    Mohamed Tharwat Hegazy1, Amina Maher2, Tareq Algarf2, Manar Abdul-Aziz2, Osama Ashraf Wafa Mohamed3, Luca Quartuccio4, Naguib Zoheir2, Salvatore De Vita5 and Gaafar Ragab6, 1Faculty of Medicine, Cairo University, Cairo, Egypt, 2Cairo University, Cairo, Egypt, 3Newgiza University, Cairo, Egypt, 4Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, Udine, Italy, 5Udine University, Udine, Italy, 6Cairo University, Egypt, Cairo, Egypt

    Background/Purpose: Hepatitis C virus (HCV) is often associated with autoimmune features and extra-hepatic manifestations. Sicca symptoms are reported in about 30% of the cases. Both…
  • 1
  • 2
  • 3
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology